AstraZeneca PLC (AZN)vsLifestance Health Group Inc (LFST)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
LFST
Lifestance Health Group Inc
$7.41
-3.01%
HEALTHCARE · Cap: $2.94B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3943% more annual revenue ($60.44B vs $1.49B). AZN leads profitability with a 17.2% profit margin vs 1.6%. AZN trades at a lower P/E of 27.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
LFST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+33.6%
Fair Value
$10.44
Current Price
$7.41
$3.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 1927.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 21.2% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Distress zone — elevated risk
ROE of 1.6% — below average capital efficiency
1.6% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : LFST
The strongest argument for LFST centers on EPS Growth, Debt/Equity, Price/Book. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : LFST
The primary concerns for LFST are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 128.5x leaves little room for execution misses. Thin 1.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while LFST is a growth play — different risk/reward profiles.
LFST carries more volatility with a beta of 1.20 — expect wider price swings.
LFST is growing revenue faster at 21.2% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 56/100), backed by strong 17.2% margins and 12.5% revenue growth. LFST offers better value entry with a 33.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Lifestance Health Group Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
LifeStance Health Group, Inc., provides outpatient mental health services to children, adolescents, adults and geriatrics. The company is headquartered in Scottsdale, Arizona.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?